Bpifrance

developing space-inspired villages on Earth

NAWATECHNOLOGIES, Société anonyme designs, develops, industrializes, and commercializes products based on organized nanostructures to enable improvements in materials and devices dedicated to energy, transportation, and environment markets. The company offers multifunctional materials and energy storage devices. NAWATECHNOLOGIES, Société anonyme was founded in 2013 and is based in Aix-en-Provence, France.

C12 Quantum Electronics develop reliable quantum processors with carbon nanotubes. Its unique technology reduces drastically the error rate, making the platform a prime candidate for noisy intermediate-scale quantum applications. The Paris, Ile-de-France, France-based company was formed in 2019 by Pierre and Matthieu Desjardins.

C12 Quantum Electronics develop reliable quantum processors with carbon nanotubes. Its unique technology reduces drastically the error rate, making the platform a prime candidate for noisy intermediate-scale quantum applications. The Paris, Ile-de-France, France-based company was formed in 2019 by Pierre and Matthieu Desjardins.

High value polysaccharides and pigments produced with high-output micro-algae and vertical photo-reactors.

GrAI Matter Labs utilizes biology-inspired spiking neural networks to overcome the limitations of traditional Von Neumann machines and application processors. Their massively parallel, fully programmable compute technology enables multi-modal sensor analytics and dynamic machine learning at low power levels not feasible before. Combining next generation neuromorphic compute with cutting edge silicon technologies brings AI to every edge device across the Internet of Things without the need for cloud computing support.

Honing Biosciences SAS, a bio-therapeutics company, develops and improves cell-based therapies to treat cancer and other chronic diseases. It offers molecular CellTuneTM technology that allows to develop new classes of tunable cell therapeutics to control the dynamic delivery of proteins in patients. The company offers therapies, such as CAR-T (chimeric antigen receptor T) cells therapy to kill cancer cells and Checkpoint inhibitors, a technology allowing to select small antibodies (nanobodies) based on proprietary scaffold, which they can deliver intracellularly. Its technology regulates protein expression at the cell surface or secretion of enzymes, cytokines, antibodies, and adapting the delivery of therapeutic proteins to clinical evolutions. Honing Biosciences SAS was incorporated in 2018 and is based in Paris, France.

NAWATECHNOLOGIES, Société anonyme designs, develops, industrializes, and commercializes products based on organized nanostructures to enable improvements in materials and devices dedicated to energy, transportation, and environment markets. The company offers multifunctional materials and energy storage devices. NAWATECHNOLOGIES, Société anonyme was founded in 2013 and is based in Aix-en-Provence, France.

NH TherAguix SAS, a clinical stage pharmaceutical company, develops nanomedicines for cancer, combining imaging, and radiotherapy. It offers AGuIX, a nanoparticle that is designed to improve the localization of solid tumors and the outcomes of radiation therapy by intravenous injection; allows the radiation therapy treatment for patient to determine the optimal moment to perform the irradiation; and allows to treat radioresistant cancers and to minimize the radiation therapy secondary effects by decreasing the dose to healthy tissues. The company was founded in 2015 and is based in Villeurbanne, France.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, focused on drug discovery and development for acute and chronic viral infections. Founded in 2014 by a group of scientists from the Infectiology Research Center, the company has established a unique platform to identify intracellular therapeutic targets and molecules, particularly for human pathogens. ENYO Pharma is developing treatments for significant viral infections, with ongoing programs targeting chronic hepatitis B and severe influenza. Its lead compound, EYP001, is designed to modulate FXR and reduce viral replication, while EYP002 is currently undergoing preclinical studies. The company aims to advance its pipeline into Phase II clinical trials and collaborates closely with research institutions to leverage innovative therapeutic strategies. ENYO Pharma is committed to addressing unmet medical needs in infectious and metabolic diseases, positioning itself as a leader in antiviral therapies.

Geomnia possesses specific know-how and core skills in 3D metrology, software engineering, micro and nano-scale mecatronics metrology systems engineering, and process optimization by software and measuring.

Technogenia has specializes in tungsten carbide metallurgy, Anti-wear welding products and anti-wear coating with high-power laser.

Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.

Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.

Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.